Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMYMP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to 8.6%.

  • Bristol Myers Squibb's EBITDA Margin rose 61500.0% to 8.6% in Q4 2025 from the same period last year, while for Dec 2025 it was 14.05%, marking a year-over-year increase of 319300.0%. This contributed to the annual value of 14.04% for FY2025, which is 319300.0% up from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's EBITDA Margin is 8.6%, which was up 61500.0% from 18.34% recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's EBITDA Margin ranged from a high of 21.09% in Q4 2021 and a low of 99.16% during Q1 2024
  • Its 5-year average for EBITDA Margin is 8.64%, with a median of 13.91% in 2022.
  • As far as peak fluctuations go, Bristol Myers Squibb's EBITDA Margin skyrocketed by 1418100bps in 2021, and later plummeted by -1183400bps in 2024.
  • Bristol Myers Squibb's EBITDA Margin (Quarter) stood at 21.09% in 2021, then crashed by -34bps to 13.87% in 2022, then dropped by -6bps to 13.09% in 2023, then crashed by -81bps to 2.45% in 2024, then skyrocketed by 251bps to 8.6% in 2025.
  • Its EBITDA Margin stands at 8.6% for Q4 2025, versus 18.34% for Q3 2025 and 9.63% for Q2 2025.